Table 6.
Baseline characteristics of all the participants.
| Variable | HCC (n = 165) | LC (n = 52) | BLD (n = 50) | HC (n = 49) |
|---|---|---|---|---|
| Age (years) | 52.08 ± 11.74 | 51.58 ± 12.68 | 47.46 ± 14.67 | 39.57 ± 13.40 |
| Gender (male/female) | 147/18 | 42/10 | 32/18 | 21/28 |
| AST (U/L) | 51.80 (14.80–1193.90) | 65.50 (12.00–317.00) | 17.70 (11.50–1.80) | 18.60 (11.60–42.10) |
| ALT (U/L) | 43.40 (9.6–1344.7) | 40.10 (4.00–205.00) | 17.45 (5.00–47.40) | 15.30 (7.00–107.00) |
| TBIL (mg/dl) | 14.90 (4.80–78.30) | 41.85 (7.10–618.00) | NA | NA |
| ALB (g/L) | 42.20 (27.70–52.50) | 37.55 (23.90–50.20) | NA | NA |
| PT-INR | 1.05 (0.65–1.44) | NA | NA | NA |
| HBV DNA (copies/mL) | 2127 (0–1.07E8) | 1259 (0–2.32E8) | NA | NA |
| AFP (ng/mL) | 225.3 (1.38–121.00) | 25.86 (0.5–324.50) | 4.99 (0.60–31.78) | 3.45 (0.56–32.00) |
Data are mean ± standard deviation or median (minimum-maximum) values. HCC, hepatocellular carcinoma; LC, liver cirrhosis; BLD, benign liver disease; HC, healthy control; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; ALB, albumin; PT-INR, prothrombin time-international normalized ratio; AFP, alpha-fetoprotein; NA, not available.